PRNewsWire
13 Nov 2026, 12:45 UTC · 1h ago
Impact · against what's priced in
The news is moderately positive for HURA due to the expansion of the TBS-2025 addressable market into mut NPM1 AML, though this is tempered by a precarious cash position. MRK is essentially unaffected as the mention is incidental to a partner's trial results.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
TuHURA held $1.9 million in cash and cash equivalents as of September 30, 2026.
Newpress release dated Nov 13, 2026
So whatWith 9-month operating outflows of $18.1 million, the current cash balance covers only ~1 month of operations without further draws from the credit facility.
More negative than 98% of claims this week
Continue reading
5 related stories
FDA clearance to begin a Phase 1b study of TBS-2025 in mut NPM1 AML expands the program's reach to ~35% of AML patients. However, with only $1.9 million in cash against 9-month outflows of $18.1 million, the company is heavily reliant on its remaining $40.8 million credit facility.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
The company received FDA clearance to begin a Phase 1b study of TBS-2025 in relapsed/refractory mut NPM1 acute myeloid leukemia (AML).
Newpress release dated Nov 13, 2026
So whatThis target represents ~35% of AML patients, expanding the addressable market for the TBS-2025 program starting in Q4 2026.
More positive than 85% of claims this week
TuHURA has access to a $50 million credit facility from its largest shareholder to fund operations.
Priced instanding guidance mentioned in press release
So whatSince $9.2 million was already drawn by Sept 30, approximately $40.8 million remains available to avoid immediate equity dilution.
More positive than 64% of claims this week
Research and development expenses were $3.7 million for the quarter ended September 30, 2026.
Newpress release dated Nov 13, 2026
So whatThe company expects R&D costs to rise in Q4 2026 due to the TBS-2025 manufacturing campaign.
More negative than 68% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
—
HURA hasn't traded since this ran. Last close $1.45 (Nov 12); the reaction starts at the next open.
HURA chart →
